INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Grant or awardVerified data

Pfeiffenberger Brent reported IPSC

Director, President and CEO · Century Therapeutics, Inc. · Common Stock

Side
A
Value
—
Shares
475.0K
Price
—
Executed
Feb 2, 2026
Disclosed
Feb 4, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 2 executedFeb 4, 2026 disclosed

IPSC · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 14.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    3 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IPSC

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    14
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$404
    266 sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    22
    RG
    Russotti GregorySee Remarks
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$4,993
    2,587 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    5
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$27K
    13.8K sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    19
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$3,200
    1,658 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    19
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$521
    254 sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    11
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$977
    463 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    22
    RG
    Russotti GregorySee Remarks
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$1,095
    534 sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    8
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$60K
    31.2K sh
    		Aug 14, 2026Aug 18, 2026
    traded Aug 14, 2026
    		+4dSEC FORM 4

    Evidence

    22
    RG
    Russotti GregorySee Remarks
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$5,767
    2,584 sh
    		Jun 12, 2026Jun 15, 2026
    traded Jun 12, 2026
    		+3dSEC FORM 4

    Evidence

    22
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$3,692
    1,654 sh
    		Jun 12, 2026Jun 15, 2026
    traded Jun 12, 2026
    		+3dSEC FORM 4

    Evidence

    5
    CC
    Cowan ChadChief Scientific Officer
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$802
    358 sh
    		Jun 11, 2026Jun 15, 2026
    traded Jun 11, 2026
    		+4dSEC FORM 4

    Evidence

    5
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$31K
    13.8K sh
    		Jun 11, 2026Jun 15, 2026
    traded Jun 11, 2026
    		+4dSEC FORM 4

    Evidence

    9
    LM
    Lee Han MyungDirector
    IPSCCentury Therapeutics, Inc.
    Grant or award
    		A—
    74.0K sh
    		Jun 11, 2026Jun 12, 2026
    traded Jun 11, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MP
    Murphy Martin PatrickDirector
    IPSCCentury Therapeutics, Inc.
    Grant or award
    		A—
    74.0K sh
    		Jun 11, 2026Jun 12, 2026
    traded Jun 11, 2026
    		+1dSEC FORM 4

    Evidence

    22
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$526
    249 sh
    		Jun 8, 2026Jun 9, 2026
    traded Jun 8, 2026
    		+1dSEC FORM 4

    Evidence

    22
    RG
    Russotti GregorySee Remarks
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$1,106
    524 sh
    		Jun 8, 2026Jun 9, 2026
    traded Jun 8, 2026
    		+1dSEC FORM 4

    Evidence

    5
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$986
    463 sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    8
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$73K
    31.2K sh
    		May 15, 2026May 19, 2026
    traded May 15, 2026
    		+4dSEC FORM 4

    Evidence

    17
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$618
    264 sh
    		May 4, 2026May 6, 2026
    traded May 4, 2026
    		+2dSEC FORM 4

    Evidence

    24
    MP
    Murphy Martin PatrickDirector
    IPSCCentury Therapeutics, Inc.
    Grant or award
    		A—
    88.0K sh
    		Dec 9, 2025Apr 10, 2026
    traded Dec 9, 2025
    		+122dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002001162-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 2, 2026
    Published
    Feb 4, 2026
    Ingested by INSIDER
    Nov 5, 04:19 UTC
    Last re-read
    Nov 5, 04:19 UTC

    Extracted facts

    Filer
    Pfeiffenberger Brent
    Role
    Director, President and CEO
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Century Therapeutics, Inc.
    Ticker
    IPSC
    Shares
    475.0K
    Price per share
    $0
    Execution date (reported)
    Feb 2, 2026
    Owned after transaction
    3.80M shares
    Days from execution to publication
    2

    What this establishes

    Pfeiffenberger Brent filed this Form 4 reporting a grant or award of IPSC on Feb 2, 2026. It became public on Feb 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President and CEO
    Pfeiffenberger Brentcik:0002001162
    Issuer
    Century Therapeutics, Inc.cik:0001850119

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.